Search

Your search keyword '"Kahatt, C."' showing total 190 results
Start Over Author "Kahatt, C."
190 results on '"Kahatt, C."'

3. EP13.07-06 Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients

Author

Trigo, J.M., primary, Besse, B., additional, Zaman, K., additional, Sala, M.Á., additional, Moreno, V., additional, López, R., additional, Lopez-Vilariño, J.A., additional, Fernandez, C., additional, Nieto, A., additional, Kahatt, C., additional, Zeaiter, A., additional, Antón, A., additional, Valdivia, J., additional, Wanesson, L., additional, and Subbiah, V., additional

Published
2023
Full Text
View/download PDF

4. P2.17-06 Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial

Author

Navarro, A., primary, Smit, E., additional, Carcereny, E., additional, Gutierrez, V., additional, Mavroudis, D., additional, Reinmuth, N., additional, Bustin, F., additional, Lopez-Vilariño, J.A., additional, Gómez, J., additional, Kahatt, C., additional, Zeaiter, A., additional, Cousin, S., additional, Ciuleanu, T.E., additional, Lungulescu, D., additional, Robev, B., additional, and Paz-Ares, L., additional

Published
2023
Full Text
View/download PDF

8. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)

Author

Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D, Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., Lorusso D., Gaillard, S, Oaknin, A, Ray-Coquard, I, Vergote, I, Scambia, G, Colombo, N, Fernandez, C, Alfaro, V, Kahatt, C, Nieto, A, Zeaiter, A, Aracil, M, Vidal, L, Pardo-Burdalo, B, Papai, Z, Kristeleit, R, O'Malley, D, Benjamin, I, Pautier, P, Lorusso, D, Gaillard S., Oaknin A., Ray-Coquard I., Vergote I., Scambia G., Colombo N., Fernandez C., Alfaro V., Kahatt C., Nieto A., Zeaiter A., Aracil M., Vidal L., Pardo-Burdalo B., Papai Z., Kristeleit R., O'Malley D. M., Benjamin I., Pautier P., and Lorusso D.

Abstract

Objective: The randomized phase 3 CORAIL trial evaluated whether lurbinectedin improved progression-free survival (PFS) compared to pegylated liposomal doxorubicin (PLD) or topotecan in patients with platinum-resistant ovarian cancer. Methods: Patients were randomly assigned (1:1) to lurbinectedin 3.2 mg/m2 1-h i.v. infusion q3wk (experimental arm), versus PLD 50 mg/m2 1-h i.v. infusion q4wk or topotecan 1.50 mg/m2 30-min i.v. infusion Days 1–5 q3wk (control arm). Stratification factors were PS (0 vs. ≥1), prior PFI (1–3 months vs. >3 months), and prior chemotherapy lines (1–2 vs. 3). The primary endpoint was PFS by Independent Review Committee in all randomized patients. This study was registered with ClinicalTrials.gov, NCT02421588. Results: 442 patients were randomized: 221 in lurbinectedin arm and 221 in control arm (127 PLD and 94 topotecan). With a median follow-up of 25.6 months, median PFS was 3.5 months (95% CI, 2.1–3.7) in the lurbinectedin arm and 3.6 months (95% CI, 2.7–3.8) in the control arm (stratified log-rank p = 0.6294; HR = 1.057). Grade ≥ 3 treatment-related adverse events (AEs) were most frequent in the control arm: 64.8% vs. 47.9% (p = 0.0005), mainly due to hematological toxicities. The most common grade ≥ 3 AEs were: fatigue (7.3% of patients) and nausea (5.9%) with lurbinectedin; mucosal inflammation (8.5%) and fatigue (8.0%) in the control arm. Conclusions: The primary endpoint of improvement in PFS was not met. Lurbinectedin showed similar antitumor efficacy and was better tolerated than current standard of care in patients with platinum-resistant ovarian cancer.

Published
2021

9. 1790P Phase II data of lurbinectedin (LUR) and irinotecan (IRI) in relapsed small cell lung cancer (SCLC) patients (pts) with chemotherapy-free interval (CTFI)>30 days (d)

Author

Zugazagoitia, J., Falcon Gonzalez, A., Navarro Mendivil, A.F., Sanchez Gastaldo, A., Simoes da Rocha, P.F., Cote, G.M., Bockorny, B., Molina Cerrillo, J., Artal, A., Baena Espinar, J., Gil Torralvo, A., Ponce Aix, S., Bote De Cabo, H., Martinez Perez, J., Martínez, S., López-Vilariño, J.A., Kahatt, C., Gómez, J., and Paz-Ares, L.G.

Published
2024
Full Text
View/download PDF

12. MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer

Author

Subbiah, V., primary, Paz-Ares, L., additional, Besse, B., additional, Zaman, K., additional, Sala, M.A., additional, Fernández, C., additional, Siguero, M., additional, Kahatt, C., additional, Lopez-Vilariño, J.A., additional, Zeaiter, A., additional, Arrondeau, J., additional, Delord, J., additional, Martínez, M., additional, Wannesson, L., additional, Antón, A., additional, and Trigo, J.M., additional

Published
2021
Full Text
View/download PDF

13. PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial

Author

Paz-Ares, L., primary, Ciuleanu, T., additional, Navarro, A., additional, Fulop, A., additional, Cousin, S., additional, Bonanno, L., additional, Smit, E., additional, Chiappori, A., additional, Olmedo, M.E., additional, Horvath, I., additional, Grohé, C., additional, Lopez-Vilariño, J.A., additional, Nuñez, R., additional, Nieto, A., additional, Cullell, M., additional, Vasco, N., additional, Kahatt, C., additional, Zeaiter, A., additional, Carcereny, E., additional, Roubec, J., additional, Syrigos, K., additional, Lo, G., additional, and Barneto, I., additional

Published
2021
Full Text
View/download PDF

19. OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial

Author

Ponce-Aix, S., primary, Coté, G., additional, Falcón, A., additional, Jimenez-Aguilar, E., additional, Lin, J., additional, Sánchez Simón, I., additional, Flor, M.J., additional, Nuñez, R., additional, Jimenez, A.M., additional, Jimenez, E., additional, Extremera, S., additional, Kahatt, C., additional, Zeaiter, A., additional, and Paz-Ares, L., additional

Published
2021
Full Text
View/download PDF

20. MO01.09 Phase 2 Basket Trial of Lurbinectedin in Small-Cell Lung Cancer (SCLC): Analysis of Efficacy by Baseline Characteristics

Author

Sands, J., primary, Paz-Ares, L., additional, Besse, B., additional, Peters, S., additional, Sala, M.A., additional, López-Vilariño, J.A., additional, Fernández, C., additional, Kahatt, C., additional, Zeaiter, A., additional, Nieto, A., additional, Siguero, M., additional, Zaman, K., additional, Arrondeau, J., additional, Delord, J.-P., additional, Martínez, M., additional, Antón, A., additional, Awada, A., additional, Kristeleit, R., additional, Olmedo, M.E., additional, Rubio, M.J., additional, Sarantopoulos, J., additional, Mosquera-Martinez, J., additional, D’Arcangelo, M., additional, Santoro, A., additional, Trigo, José M., additional, and Subbiah, V., additional

Published
2021
Full Text
View/download PDF

21. MO01.10 Activity of Lurbinectedin in Second-line SCLC Patients Who Are Candidates for Platinum Rechallenge

Author

Subbiah, V., primary, Paz-Ares, L., additional, Besse, B., additional, Zaman, K., additional, Sala, M.A., additional, López-Vilariño, J.A., additional, Fernández, C., additional, Kahatt, C., additional, Siguero, M., additional, Zeaiter, A., additional, Arrondeau, J., additional, Delord, J.-P., additional, Martínez, M., additional, Antón, A., additional, Trigo, José M., additional, and Wannesson, L., additional

Published
2021
Full Text
View/download PDF

22. MO01.08 Phase 2 Basket Trial of Lurbinectedin in Second-line SCLC: Characteristics and Outcomes in Treatment Responders

Author

Subbiah, V., primary, Paz-Ares, L., additional, Besse, B., additional, Moreno, V., additional, Peters, S., additional, Sala, M.A., additional, López-Vilariño, J.A., additional, Fernández, C., additional, Kahatt, C., additional, Zeaiter, A., additional, Zaman, K., additional, Delord, J.-P., additional, Martínez, M., additional, Antón, A., additional, Awada, A., additional, Kristeleit, R., additional, Olmedo, M.E., additional, Rubio, M.J., additional, Sarantopoulos, J., additional, D’Arcangelo, M., additional, Santoro, A., additional, Trigo, José M., additional, and Sands, J., additional

Published
2021
Full Text
View/download PDF

23. 1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge

Author

Subbiah, V., primary, Paz-Ares, L., additional, Besse, B., additional, Moreno, V., additional, Zaman, K., additional, Sala Gonzalez, M.A., additional, Lopez-Vilarino, J.A., additional, Fernandez, C.M., additional, Kahatt, C., additional, Siguero, M., additional, Zeaiter, A., additional, Lopez Lopez, R., additional, Ponce Aix, S., additional, Boni, V., additional, Arrondeau, J., additional, Delord, J-P., additional, Martínez-Aguillo, M., additional, Wannesson De Nicola, L., additional, Anton Torres, A., additional, and Trigo Perez, J.M., additional

Published
2020
Full Text
View/download PDF

25. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

Author

Spicka, I., Ocio, E.M. (E.), Oakervee, H.E., Greil, R., Banh, R.H., Huang, S.Y., D'Rozario, J.M., Dimopoulos, M.A. (Meletios), Martinez, S., Extremera, S., Kahatt, C., Alfaro, V. (Vicente), Carella, AM, Meuleman, N., Hàjek, R. (Roman), Symeonidis, A., Min, C.K., Cannell, P., Ludwig, H. (Heinz), Sonneveld, P. (Pieter), Mateos, M.V., Spicka, I., Ocio, E.M. (E.), Oakervee, H.E., Greil, R., Banh, R.H., Huang, S.Y., D'Rozario, J.M., Dimopoulos, M.A. (Meletios), Martinez, S., Extremera, S., Kahatt, C., Alfaro, V. (Vicente), Carella, AM, Meuleman, N., Hàjek, R. (Roman), Symeonidis, A., Min, C.K., Cannell, P., Ludwig, H. (Heinz), Sonneveld, P. (Pieter), and Mateos, M.V.

Abstract

The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and lenalidomide or thalidomide. Patients were randomly assigned (2:1) to receive plitidepsin 5 mg/m2 on D1 and D15 plus DXM 40 mg on D1, D8, D15, and D22 (arm A, n = 171) or DXM 40 mg on D1, D8, D15, and D22 (arm B, n = 84) q4wk. The primary endpoint was progression-free survival (PFS). Median PFS without disease progression (PD) confirmation (IRC assessment) was 2.6 months (arm A) and 1.7 months (arm B) (HR = 0.650; p = 0.0054). Median PFS with PD confirmation (investigator’s assessment) was 3.8 months (arm A) and 1.9 months (arm B) (HR = 0.611; p = 0.0040). Median overall survival (OS, intention-to-treat analysis) was 11.6 months (arm A) and 8.9 months (arm B) (HR = 0.797; p = 0.1261). OS improvement favoring arm A was found when discounting a crossover effect (37 patients crossed over from arm B to arm A) (two-stage method; HR = 0.622; p = 0.0015). The most common grade 3/4 treatment-related adverse events (% of patients arm A/arm B) were fatigue (10.8%/1.2%), myalgia (5.4%/0%), and nausea (3.6%/1.2%), being usually transient and reversible. The safety profile does not overlap with the toxicity observed with other agents used in multiple myeloma. In conclusion, efficacy data, the reassuring safety profile, and the novel mechanism of action of plitidepsin suggest that this combination can be an alternative option in patients with relapsed/refractory multiple myeloma after at least three prior therapy lines.

Published
2019
Full Text
View/download PDF

26. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma

Author

Spicka, I, Ocio, EM, Oakervee, HE, Greil, R, Banh, RH, Huang, SY, D'Rozario, JM, Dimopoulos, MA, Martinez, S, Extremera, S, Kahatt, C, Alfaro, V, Carella, AM, Meuleman, N, Hajek, R, Symeonidis, A, Min, CK, Cannell, P, Ludwig, H, Sonneveld, Pieter, Mateos, MV, Spicka, I, Ocio, EM, Oakervee, HE, Greil, R, Banh, RH, Huang, SY, D'Rozario, JM, Dimopoulos, MA, Martinez, S, Extremera, S, Kahatt, C, Alfaro, V, Carella, AM, Meuleman, N, Hajek, R, Symeonidis, A, Min, CK, Cannell, P, Ludwig, H, Sonneveld, Pieter, and Mateos, MV

Published
2019

28. P2.12-13 Lurbinectedin (L) Combined with Paclitaxel (P) or Irinotecan (I) in Relapsed SCLC. Results from Two Phase Lb Trials

Author

Ponce, S., primary, Calvo, E., additional, De Miguel, M.J., additional, Sessa, C., additional, Flor, M.J., additional, Drilon, A., additional, Falcon, A., additional, Simon, I. Sanchez, additional, Nuñez, R., additional, Luepke, X.E., additional, Cuevas-Melendez, N., additional, López-Vilariño, J., additional, Fudio, S., additional, Siguero, M., additional, Cullell-Young, M., additional, Kahatt, C., additional, Zeaiter, A., additional, and Paz-Ares, L., additional

Published
2019
Full Text
View/download PDF

30. P1.12-03 Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring ≥30 Days After Last Platinum Dose

Author

Trigo Perez, J.M., primary, Subbiah, V., additional, Besse, B., additional, Moreno, V., additional, López, R., additional, Sala, M.a., additional, Ponce, S., additional, Fernendez, C., additional, Nieto, A., additional, Kahatt, C., additional, Zeaiter, A., additional, Zaman, K., additional, Boni, V., additional, Arrondeau, J., additional, Martinez, M., additional, Delord, J., additional, Awada, A., additional, Kristeleit, R., additional, Longo, F., additional, Sarantopoulos, J., additional, Rubio, M., additional, Anton, A., additional, Wannesson, L., additional, Valdivia, J., additional, Shappiro, G., additional, Villalobos, V., additional, Santoro, A., additional, D'Arcangelo, M., additional, Aparicio, L., additional, and Paz-Ares, L., additional

Published
2019
Full Text
View/download PDF

32. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial

Author

Gaillard, S., primary, Oaknin, A., additional, Ray-Coquard, I.L., additional, Vergote, I.B., additional, Scambia, G., additional, Colombo, N., additional, Ghamande, S.A., additional, Soto-Matos, A., additional, Fernandez, C.M., additional, Kahatt, C., additional, Gomez, J., additional, Nieto, A., additional, Torres, N., additional, Pardo-Burdalo, B., additional, Papai, Z., additional, Kristeleit, R.S., additional, O’Malley, D.M., additional, Benjamin, I., additional, Pautier, P., additional, and Lorusso, D., additional

Published
2018
Full Text
View/download PDF

38. Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial

Author

Balmaña, J., primary, Cruz, C., additional, Arun, B.K., additional, Telli, M., additional, Garber, J., additional, Domchek, S., additional, Fernandez, C.M., additional, Kahatt, C., additional, Szyldergemajn, S., additional, Soto-Matos, A., additional, Haza, A. Perezdela, additional, Fidalgo, J.A. Perez, additional, Lluch-Hernandez, A., additional, Antolin, S., additional, Tung, N.M., additional, Vahdat, L.T., additional, Lopez, R., additional, and Isakoff, S.J.J., additional

Published
2016
Full Text
View/download PDF

41. Role of trabectedin in BRCA-mutated patients

Author

Lorusso, D., Kahatt, C., Lardelli, P., Lorusso, D., Kahatt, C., and Lardelli, P.

Abstract

Trabectedin, approved for the treatment of adult patients with advanced soft tissue sarcoma (STS), after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents, and in combination with pegylated liposomal doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer (ROC), has a complex multi-targeted mechanism of action. Not only does trabectedin interact with DNA binding proteins and modulate transcription leading to cell-cycle arrest, growth inhibition and cancer cell death, it also has activity in the tumour microenvironment and may inhibit epithelial-mesenchymal transition, thus preventing epithelial cancer cells becoming more aggressive and thus reducing their metastatic potential and preventing development of resistance to chemotherapy. Differences in the cancer cell DNA repair mechanism appear to affect sensitivity to trabectedin, with those deficient in homologous recombination (HR) being highly sensitive to trabectedin and nucleotide excision repair-deficient cells being less sensitive to trabectedin. As trabectedin-induced damage requires repair of DNA-double-stranded breaks, this pathway appears to be pivotal for drug-induced cytotoxicity and response to trabectedin. It was hypothesized that differential expression of factors involved in DNA repair, such as the protein nibrin, may affect clinical outcomes of patients with ROC. Indeed low nibrin expression seems to be associated with significantly better clinical outcome in patients with platinum-sensitive disease treated with the combination of trabectedin plus PLD, but not in with PLD alone. The accumulating evidence of the existence of a sub-set of tumours with defects in the HR-DNA repair pathway, – the BRCAness phenotype – suggests that these patients should benefit more from trabectedin-based therapy. Early data show that this may be true for patients with STS and metastatic breast cancer (MBC) suggesting a potential role for trabected

Published
2014

44. Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC)

Author

Isakoff, SJ, primary, Cruz, C, additional, Garber, J, additional, LLuch, A, additional, Perez Fidalgo, JA, additional, Tung, N, additional, Fernandez, C, additional, Kahatt, C, additional, Szyldergemajn, S, additional, Soto Matos-Pita, A, additional, Baselga, J, additional, and Balmaña, J, additional

Published
2013
Full Text
View/download PDF

45. Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

Author

Plummer, R, primary, Lorigan, P, additional, Brown, E, additional, Zaucha, R, additional, Moiseyenko, V, additional, Demidov, L, additional, Soriano, V, additional, Chmielowska, E, additional, Andrés, R, additional, Kudryavtseva, G, additional, Kahatt, C, additional, Szyldergemajn, S, additional, Extremera, S, additional, de Miguel, B, additional, Cullell-Young, M, additional, and Calvert, H, additional

Published
2013
Full Text
View/download PDF

46. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

Author

Ribrag, V., primary, Caballero, D., additional, Ferme, C., additional, Zucca, E., additional, Arranz, R., additional, Briones, J., additional, Gisselbrecht, C., additional, Salles, G., additional, Gianni, A. M., additional, Gomez, H., additional, Kahatt, C., additional, Corrado, C., additional, Szyldergemajn, S., additional, Extremera, S., additional, de Miguel, B., additional, Cullell-Young, M., additional, and Cavalli, F., additional

Published
2012
Full Text
View/download PDF

47. Lurbinectedin (PM01183) Activity in Platinum-Resistant/Refractory Ovarian Cancer Patients. Preliminary Results of an Ongoing Two-Stage Phase II Study

Author

Berton-Rigaud, D., primary, Alexandre, J., additional, Provansal, M., additional, Casado, A., additional, Martin, A. Gonzalez, additional, Fernández, C., additional, Kahatt, C., additional, Szyldergemajn, S., additional, Del Campo, J.M., additional, Poveda, A.M., additional, Guerra, E.M., additional, and Ray-Coquard, I., additional

Published
2012
Full Text
View/download PDF

50. Phase I study of PM00104 in combination with carboplatin (C) in patients (pts) with advanced solid tumors.

Author

Calvo, E., primary, Gil, M., additional, Coronado, C., additional, Valer, A., additional, Duran, I., additional, Hidalgo, M., additional, Pardo, B., additional, Calles, A., additional, García, M., additional, Morelli, P., additional, Kahatt, C. M., additional, Prados, R., additional, Fernandez, C., additional, and Salazar, R., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results